This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (23)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Social Bookmarking   What's this?

From Clinical Trials to Clinical Practice

J. P. Mohr, MD

JAMA. 2000;283:1189-1191.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Intravenous tissue-type plasminogen activator (tPA) for ischemic stroke has broken a major therapeutic barrier, and much more progress is certain to follow. Steadily accumulating data continue to justify current guidelines for use of tPA in stroke,¹ and demonstrate that low complication rates can be achieved with proper use of this therapy. Renewed interest in hyperacute treatment of stroke may breathe new life into neuroprotective agents and acute interventional and surgical therapies, alone or with tPA.

Two studies^2-3 in this issue of THE JOURNAL reflect 2 perspectives on the tPA experience. In the first, Albers and colleagues² present data from a prospective, multicenter study that provides further evidence that physicians with experience using tPA can replicate the favorable outcomes and similar complication rates reported in earlier studies.^4-6 Of 389 enrolled patients, the 30-day mortality rate was 13% and the rate of intracerebral hemorrhage at 3 days was . . . [Full Text of this Article]

Author Affiliation: Neurological Institute, New York, NY.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Intravenous Tissue-Type Plasminogen Activator for Treatment of Acute Stroke: The Standard Treatment with Alteplase to Reverse Stroke (STARS) Study
Gregory W. Albers, Vernice E. Bates, Wayne M. Clark, Rodney Bell, Piero Verro, and Scott A. Hamilton
JAMA. 2000;283(9):1145-1150.
ABSTRACT | FULL TEXT  

Use of Tissue-Type Plasminogen Activator for Acute Ischemic Stroke: The Cleveland Area Experience
Irene L. Katzan, Anthony J. Furlan, Lynne E. Lloyd, Jeffrey I. Frank, Dwain L. Harper, Judith A. Hinchey, Jeffrey P. Hammel, Annie Qu, and Cathy A. Sila
JAMA. 2000;283(9):1151-1158.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Normobaric Hyperoxia Reduces the Neurovascular Complications Associated With Delayed Tissue Plasminogen Activator Treatment in a Rat Model of Focal Cerebral Ischemia
Liu et al.
Stroke 2009;40:2526-2531.
ABSTRACT | FULL TEXT  

Thrombolysis for acute stroke with special emphasis on the very old: experience from a single Dutch centre.
van Oostenbrugge et al.
J. Neurol. Neurosurg. Psychiatry 2006;77:375-377.
ABSTRACT | FULL TEXT  

Braving New Worlds: To Conquer, to Endure
Moffat
ptjournal 2004;84:1056-1086.
ABSTRACT | FULL TEXT  

Efficacy of IV tissue plasminogen activator in acute stroke: Does stroke subtype really matter?
Hsia et al.
Neurology 2003;61:71-75.
ABSTRACT | FULL TEXT  

Frequency of Thrombolytic Therapy in Patients With Acute Ischemic Stroke and the Risk of In-Hospital Mortality: The German Stroke Registers Study Group
Heuschmann et al.
Stroke 2003;34:1106-1112.
ABSTRACT | FULL TEXT  

CT and Conventional and Diffusion-weighted MR Imaging in Acute Stroke: Study in 691 Patients at Presentation to the Emergency Department
Mullins et al.
Radiology 2002;224:353-360.
ABSTRACT | FULL TEXT  

Adherence to Postacute Rehabilitation Guidelines Is Associated With Functional Recovery in Stroke * Editorial Comment
Duncan et al.
Stroke 2002;33:167-178.
ABSTRACT | FULL TEXT  

Treatment With Tissue Plasminogen Activator and Inpatient Mortality Rates for Patients With Ischemic Stroke Treated in Community Hospitals Editorial Comment
Reed et al.
Stroke 2001;32:1832-1840.
ABSTRACT | FULL TEXT  

Use of Tissue Plasminogen Activator to Revive Blebs Following Intraocular Surgery
Smith and Doyle
Arch Ophthalmol 2001;119:809-812.
ABSTRACT | FULL TEXT  

Utilization of Intravenous Tissue-Type Plasminogen Activator for Ischemic Stroke at Academic Medical Centers : The Influence of Ethnicity Editorial Comment : It Is Time to Implement Stroke Practice Improvement Programs and Prevent the Racial Disparity in Stroke Care
Johnston et al.
Stroke 2001;32:1061-1068.
ABSTRACT | FULL TEXT  

Intravenous tPA for Ischemic Stroke Team Performance Over Time, Safety, and Efficacy in a Single-Center, 2-Year Experience
Koennecke et al.
Stroke 2001;32:1074-1078.
ABSTRACT | FULL TEXT  

Neuroprotection in Acute Ischemic Stroke
Plum
JAMA 2001;285:1760-1761.
FULL TEXT  

Mixed Results with Thrombolysis for Stroke
JWatch General 2000;2000:2-2.
FULL TEXT